Abstract
Despite accumulating clinical evidence supporting a key role for venous congestion in the development of acute decompensated heart failure (ADHF), there remain several gaps in our knowledge of the pathophysiology of ADHF. Specifically, the biomechanically driven effects of venous congestion on the vascular endothelium (the largest endocrine/paracrine organ of the body), on neurohormonal activation, and on renal and cardiac dysfunction remain largely unexplored. We propose that venous congestion is a fundamental, hemodynamic stimulus for vascular inflammation, which plays a key role in the development and possibly the resolution of ADHF through vascular, humoral, renal, and cardiac mechanisms. A better understanding of the role of venous congestion and endothelial activation in the pathophysiology of ADHF may provide a strong rationale for near-future testing of treatment strategies that target biomechanically driven inflammation. Targeting vascular and systemic inflammation before symptoms arise may prevent progression to overt clinical decompensation in the ADHF syndrome.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Lloyd-Jones D, Adams R, Carnethon M, et al.: Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:480–486.
Gheorghiade M, Zannad F, Sopko G, et al.: Acute heart failure syndromes: current state and framework for future research. Circulation 2005, 112:3958–3968.
Fonarow GC, Heywood JT, Heidenreich PA, et al.: Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007, 153:1021–1028.
Yu CM, Wang L, Chau E, et al.: Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 2005, 112:841–848.
• Chaudhry SI, Wang Y, Concato J, et al.: Patterns of weight change preceding hospitalization for heart failure. Circulation 2007, 116:1549–1554. This case-control study links increases in body weight, which occur weeks before admission, to hospitalization for heart failure. Close monitoring of body weight identifies a high-risk preadmission period during which new interventions to avert decompensated heart failure are needed.
Lucas C, Johnson W, Hamilton MA, et al.: Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000, 140:840–847.
Gheorghiade M, Gattis WA, O’Connor CM, et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291:1963–1971.
Adamson PB, Magalski A, Braunschweig F, et al.: Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol 2003, 41:565–571.
Fonarow GC, Abraham WT, Albert NM, et al.: Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 2008, 168:847–854.
Tsuyuki RT, McKelvie RS, Arnold JM, et al.: Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 2001, 161:2337–2342.
Firth JD, Raine AE, Ledingham JG: Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1988, 1:1033–1035.
Blake WD, Wegria R, Keating RP, Ward HP: Effect of increased renal venous pressure on renal function. Am J Physiol 1949, 157:1–13.
Gheorghiade M, De Luca L, Fonarow GC, et al.: Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005, 96:11G–17G.
Colombo PC, Onat D, Sabbah HN: Acute heart failure as “acute endothelitis”–interaction of fluid overload and endothelial dysfunction. Eur J Heart Fail 2008, 10:170–175.
•• Colombo PC, Rastogi S, Onat D, et al.: Activation of endothelial cells in conduit veins of dogs with heart failure and veins of normal dogs after vascular stretch by acute volume loading. J Card Fail 2009, 15:457–463. This recent article provides mechanistic in vivo evidence for the link between systemic venous congestion and activation of the inflammatory/oxidative program in ECs. It shows that systemic fluid loading in normal dogs is sufficient to cause endothelial and neurohormonal activation to levels that approach those in dogs with heart failure.
Gimbrone MA Jr, Nagel T, Topper JN: Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest 1997, 100:S61–S65.
Pang CC: Measurement of body venous tone. J Pharmacol Toxicol Methods 2000, 44:341–360.
Vane JR, Anggard EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 1990, 323:27–36.
Aird WC: Mechanisms of endothelial cell heterogeneity in health and disease. Circ Res 2006, 98:159–162.
Gimbrone MA Jr, Topper JN, Nagel T, et al.: Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci 2000, 902:230–239.
Sumpio BE, Riley JT, Dardik A: Cells in focus: endothelial cell. Int J Biochem Cell Biol 2002, 34:1508–1512.
Sorescu GP, Song H, Tressel SL, et al.: Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res 2004, 95:773–779.
Harrison DG, Widder J, Grumbach I, et al.: Endothelial mechanotransduction, nitric oxide and vascular inflammation. J Intern Med 2006, 259:351–363.
Hasdai D, Holmes DR Jr, Garratt KN, et al.: Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation 1997, 95:357–362.
Kawai M, Naruse K, Komatsu S, et al.: Mechanical stress-dependent secretion of interleukin 6 by endothelial cells after portal vein embolization: clinical and experimental studies. J Hepatol 2002, 37:240–246.
Wang BW, Chang H, Lin S, et al.: Induction of matrix metalloproteinases-14 and -2 by cyclical mechanical stretch is mediated by tumor necrosis factor-alpha in cultured human umbilical vein endothelial cells. Cardiovasc Res 2003, 59:460–469.
Mitchell JA, Ali F, Bailey L, et al.: Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol 2008, 93:141–147.
Andrew PJ, Mayer B: Enzymatic function of nitric oxide synthases. Cardiovasc Res 1999, 43:521–531.
Drexler H: Nitric oxide synthases in the failing human heart: a doubled-edged sword? Circulation 1999, 99:2972–2975.
Bauersachs J, Bouloumie A, Fraccarollo D, et al.: Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 1999, 100:292–298.
Canty TG Jr, Boyle EM Jr, Farr A, et al.: Oxidative stress induces NF-kappaB nuclear translocation without degradation of IkappaBalpha. Circulation 1999, 100:II361–II364.
Boyle EM Jr, Canty TG Jr, Morgan EN, et al.: Treating myocardial ischemia-reperfusion injury by targeting endothelial cell transcription. Ann Thorac Surg 1999, 68:1949–1953.
Hung TH, Charnock-Jones DS, Skepper JN, Burton GJ: Secretion of tumor necrosis factor-alpha from human placental tissues induced by hypoxia-reoxygenation causes endothelial cell activation in vitro: a potential mediator of the inflammatory response in preeclampsia. Am J Pathol 2004, 164:1049–1061.
Kim SF, Huri DA, Snyder SH: Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005, 310:1966–1970.
Ennezat PV, Malendowicz SL, Testa M, et al.: Physical training in patients with chronic heart failure enhances the expression of genes encoding antioxidative enzymes. J Am Coll Cardiol 2001, 38:194–198.
•• Campese VM, Sindhu RK, Ye S, et al.: Regional expression of NO synthase, NAD(P)H oxidase and superoxide dismutase in the rat brain. Brain Res 2007, 1134:27–32. This study provides evidence for the protective effects of SOD against the pleiotropic damaging effects of reactive oxygen species. The study documents regional distributions of NO, NAD(P)H, and antioxidant enzymes such as SOD throughout the rat brain.
Feng NH, Chu SJ, Wang D, et al.: Effects of various antioxidants on endotoxin-induced lung injury and gene expression: mRNA expressions of MnSOD, interleukin-1beta and iNOS. Chin J Physiol 2004, 47:111–120.
Sies H, Sharov VS, Klotz LO, Briviba K: Glutathione peroxidase protects against peroxynitrite-mediated oxidations. A new function for selenoproteins as peroxynitrite reductase. J Biol Chem 1997, 272:27812–27817.
Colombo PC, Ashton AW, Celaj S, et al.: Biopsy coupled to quantitative immunofluorescence: a new method to study the human vascular endothelium. J Appl Physiol 2002, 92:1331–1338.
Feng L, Stern DM, Pile-Spellman J: Human endothelium: endovascular biopsy and molecular analysis. Radiology 1999, 212:655–664.
Onat D, Jelic S, Schmidt AM, et al.: Vascular endothelial sampling and analysis of gene transcripts: a new quantitative approach to monitor vascular inflammation. J Appl Physiol 2007, 103:1873–1878.
Colombo PC, Banchs JE, Celaj S, et al.: Endothelial cell activation in patients with decompensated heart failure. Circulation 2005, 111:58–62.
Wan E, Mecklai A, Klapholz M, et al.: Increased nitric oxide degradation by oxidative stress and decreased nitric oxide production by endothelial nitric oxide synthase cause severe derangement of venous nitric oxide balance in decompensated heart failure. J Am Coll Cardiol 2009 (abstract).
Colombo PC, Kebschull M, Xiang JZ, et al.: Acute venous hypertension and congestion coupled with analysis of endothelial gene expression profiling and circulating neurohormones: a new model to characterize the endothelial and inflammatory response to acute mechanical stress in humans. J Am Coll Cardiol 2009 (abstract).
Testa M, Yeh M, Lee P, et al.: Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996, 28:964–971.
Cernacek P, Stewart DJ: Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun 1989, 161:562–567.
White M, Ducharme A, Ibrahim R, et al.: Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin Sci (Lond) 2006, 110:483–489.
Yndestad A, Holm AM, Muller F, et al.: Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003, 60:141–146.
Kapadia S, Lee J, Torre-Amione G, et al.: Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995, 96:1042–1052.
Li X, Moody MR, Engel D, et al.: Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation 2000, 102:1690–1696.
Merrill AJ: Edema and decreased renal blood flow in patients with chronic congestive heart failure: evidence of “forward failure” as the primary cause of edema. J Clin Invest 1946, 25:389–400.
Mokotoff R, Ross G, Leiter L: Renal plasma flow and sodium reabsorption and excretion in congestive heart failure. J Clin Invest 1948, 27:1–9.
• Tang WH, Mullens W: Cardio-renal syndrome in decompensated heart failure. Heart 2009 Apr 27 (Epub ahead of print). This review highlights changing views of the cardiorenal syndrome by revisiting older literature that emphasizes the important role of elevated renal venous pressure, rather than impaired cardiac output, in the worsening renal function associated with CHF.
Friedman B, Clark G, Resnik H, Harrison TR: Effect of digitalis on the cardiac output of persons with congestive heart failure. Arch Intern Med 1935, 56:710–723.
Katz SD: Blood volume assessment in the diagnosis and treatment of chronic heart failure. Am J Med Sci 2007, 334:47–52.
Gibson JG, Evans WA: Clinical studies of the blood volume. III. Changes in blood volume, venous pressure and blood velocity rate in chronic congestive heart failure. J Clin Invest 1937, 16:851–858.
Seymour WB, Pritchard WH, Longley LP, Hayman JM: Cardiac output, blood and interstitial fluid volumes, total circulating serum protein, and kidney function during cardiac failure and after improvement. J Clin Invest 1942, 21:229–240.
Prentice TC, Berlin NI, Hyde GM, et al.: Total red cell volume, plasma volume, and sodium space in congestive heart failure. J Clin Invest 1951, 30:1471–1482.
Feldschuh J, Enson Y: Prediction of the normal blood volume: relation of blood volume to body habitus. Circulation 1977, 56:605–612.
Recommended methods for measurement of red-cell and plasma volume: International Committee for Standardization in Haematology [no authors listed]. J Nucl Med 1980, 21:793–800.
Androne AS, Hryniewicz K, Hudaihed A, et al.: Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol 2004, 93:1254–1259.
Winton FR: The influence of venous pressure on the isolated mammalian kidney. J Physiol 1931, 72:49–61.
Kostreva DR, Seagard JL, Castaner A, Kampine JP: Reflex effects of renal afferents on the heart and kidney. Am J Physiol 1981, 241:R286–R292.
Haddy FJ: Effect of elevation of intraluminal pressure on renal vascular resistance. Circ Res 1956, 4:659–663.
Dilley JR, Corradi A, Arendshorst WJ: Glomerular ultrafiltration dynamics during increased renal venous pressure. Am J Physiol 1983, 244:F650–F658.
Abildgaard U, Henriksen O, Amtorp O: Sympathetic reflex-induced vasoconstriction during renal venous stasis elicited from the capsule in the dog kidney. Acta Physiol Scand 1985, 123:1–8.
Aiken JW, Vane JR: Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther 1973, 184:678–687.
Yanagisawa M, Kurihara H, Kimura S, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411–415.
Sakurai T, Yanagisawa M, Masaki T: Molecular characterization of endothelin receptors. Trends Pharmacol Sci 1992, 13:103–108.
Corradi A, Arendshorst WJ: Rat renal hemodynamics during venous compression: roles of nerves and prostaglandins. Am J Physiol 1985, 248:F810–F820.
Myers SI, Zipser R, Needleman P: Peptide-induced prostaglandin biosynthesis in the renal-vein-constricted kidney. Biochem J 1981, 198:357–363.
Ahlborg G, Lundberg JM: Cyclooxygenase inhibition potentiates the renal vascular response to endothelin-1 in humans. J Appl Physiol 1998, 85:1661–1666.
Acknowledgments
Dr. Paolo C. Colombo's work is supported by an NIH R01 HL-3001996. Dr. Ryan T. Demmer's work is supported by an NIH K99 DE-018739.
Disclosure
Dr. Paolo C. Colombo has received an investigator-initiated research grant (NCT000698139) from Medtronic, Inc. No other potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ganda, A., Onat, D., Demmer, R.T. et al. Venous Congestion and Endothelial Cell Activation in Acute Decompensated Heart Failure. Curr Heart Fail Rep 7, 66–74 (2010). https://doi.org/10.1007/s11897-010-0009-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11897-010-0009-5